NCT04959097 Retinoblastoma Patient Clinical Database and Tissue Repository
| NCT ID | NCT04959097 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Hospital Los Angeles |
| Condition | Retinoblastoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2017-01-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2017-01-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed. Given this limitation, we use aqueous humor (AH), the clear fluid in the front of the eye to detect specific markers, or information, that comes from the tumor itself.
Eligibility Criteria
Inclusion Criteria: * All patients, age 0 days to 18 years, with a diagnosis unilateral or bilateral retinoblastoma (RB) seen at CHLA (Children's Hospital Los Angeles). Exclusion Criteria: * Patients referred for second opinions only and not treated at CHLA for any reason.
Contact & Investigator
Jesse L Berry, MD
PRINCIPAL INVESTIGATOR
Children's Hospital Los Angeles
Frequently Asked Questions
Who can join the NCT04959097 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 18 Years, studying Retinoblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04959097 currently recruiting?
Yes, NCT04959097 is actively recruiting participants. Contact the research team at jberry@chla.usc.edu for enrollment information.
Where is the NCT04959097 trial being conducted?
This trial is being conducted at Phoenix, United States, Los Angeles, United States, Atlanta, United States, Chicago, United States and 5 additional locations.
Who is sponsoring the NCT04959097 clinical trial?
NCT04959097 is sponsored by Children's Hospital Los Angeles. The principal investigator is Jesse L Berry, MD at Children's Hospital Los Angeles. The trial plans to enroll 800 participants.